The Use of Curare in General Anesthesia

Griffith, Harold R.

doi:10.1097/00132586-195704000-00058

Cited by 20 publications

(22 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While hundreds of neuromuscular blocking drugs have been synthesized since the first clinical use of d-tubocurarine in 1942 [118], none are ideal, particularly for facilitating intubation. The properties of α3/5 conopeptides, however, have led to speculation that their analogs might represent rapidly biodegradable drugs which permit the use of high doses in order to gain rapid onset of action [119].…”

Section: Therapeutic Applicationsmentioning

confidence: 99%

Conotoxins: Therapeutic Potential and Application

Layer¹,

McIntosh

2006

Marine Drugs

View full text Add to dashboard Cite

Abstract:The pharmacological variety of conotoxins, diverse peptides found in the venoms of marine cone snails, is well recognized. Venoms from each of the estimated 500 species of cone snails contain 50 to 200 distinct biologically active peptides. Most conotoxins characterized to date target receptors and ion channels of excitable tissues, such as ligandgated nicotinic acetylcholine, N-methyl-D-aspartate, and type 3 serotonin receptors, as well as voltage-gated calcium, sodium, and potassium channels, and G-protein-coupled receptors including α-adrenergic, neurotensin, and vasopressin receptors, and the norepinephrine transporter. Several conotoxins have shown promise in preclinical models of pain, convulsive disorders, stroke, neuromuscular block, and cardioprotection. The pharmacological selectivity of the conotoxins, coupled with the safety and efficacy demonstrated in preclinical models, has led to their investigation as human therapeutic agents. In the following review, we will survey the pharmacology and therapeutic rationale of those conotoxins with potential clinical application, and discuss the unique challenges that each will face in the course of their transition from venom component to human therapeutic.

show abstract

Section: Therapeutic Applicationsmentioning

confidence: 99%

Conotoxins: Therapeutic Potential and Application

Layer¹,

McIntosh

2006

Marine Drugs

View full text Add to dashboard Cite

show abstract

“…118 Furthermore, for many procedures spinal anesthesia also provided excellent muscle relaxation (especially attractive in the early days of using neuromuscular blocking drugs, which were introduced clinically in 1942). 119 Proponents of regional anesthesia, such as Dr. John Bonica, were of the opinion that these techniques were underutilized during the 1950s. 120 Although the reasons for this practice would have had many causes, one factor must have been that during this decade spinal anesthesia was generally reported as having a 10% to 15% incidence of PDPH (15%-20% in obstetrics).…”

Section: Spinal Anesthesia In the 1950smentioning

confidence: 99%

Postdural Puncture Headache and the Development of the Epidural Blood Patch

Harrington

2004

Regional Anesthesia and Pain Medicine

View full text Add to dashboard Cite

“…In 1942, in Montreal, Griffith and Johnson introduced the use of small amounts of curare to enhance abdominal muscle relaxation during laparotomy, still relying on the diaphragm to ventilate the lungs 2. Patients were made merely weak and not paralysed while receiving a full inhalation anaesthetic.…”

Section: Less May Be Bettermentioning

confidence: 99%

Neuromuscular blockers during general anaesthesia

Ponte¹

1995

BMJ

View full text Add to dashboard Cite

The Use of Curare in General Anesthesia

Cited by 20 publications

References 0 publications

Conotoxins: Therapeutic Potential and Application

Conotoxins: Therapeutic Potential and Application

Postdural Puncture Headache and the Development of the Epidural Blood Patch

Neuromuscular blockers during general anaesthesia

Contact Info

Product

Resources

About